Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase 2 Study of Lisaftoclax Plus Pirtobrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma After Failure of BTK-Targeted Therapy

NCT07684950 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT07684950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07684950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase 2 Study of Lisaftoclax Plus Pirtobrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma After Failure of BTK-Targeted Therapy
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
April 30, 2029
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma (mcl)